Clinical Research Directory
Browse clinical research sites, groups, and studies.
Innate T Cells and TKI Discontinuation
Sponsor: Poitiers University Hospital
Summary
After more than a decade of treating chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI), the discontinuation of treatment represents the expected new revolution. The investigators has recently discovered a new innate CD8+ T population in healthy subjects, the Eomes+ KIR+ CD8+ T population, with anti-tumor properties. Remarkably, these cells are numerically and functionally deficient in patients at diagnosis and then restored in patients in major molecular remission (MMR) on TKI. Our work performed in a retrospective pilot study interestingly shows a very significant increase in the proportion of CD8+ Eomes+ KIR+ T cells within total T cells in patients with prolonged success in stopping their ITK (≥ 2 years).Thus, the investigators postulate that CD8+ Eomes+ KIR+ T cells are a predictive signature of TKI arrest success in CML. The investigators will rely on a prospective translational study of this cell contingent during treatment cessation.
Official title: Innate T-cells as a Biomarker of Successful TKI Arrest in Chronic Myeloid Leukemia
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
OBSERVATIONAL
Enrollment
92
Start Date
2021-04-20
Completion Date
2028-04
Last Updated
2023-08-04
Healthy Volunteers
Not specified
Conditions
Interventions
Characteristics of innate T cells
functional and phenotypic characteristics of innate T cells
Locations (1)
C.H.U. de Poitiers
Poitiers, France